Payer National Outcomes Director — VIASKIN® Peanut East

About the role

The National Outcomes Director serves as a scientific expert and a key point of contact between DBV Technologies and external payer and population health decision-makers. This role is crucial for ensuring that population health decision-makers have a clear, accurate, and timely understanding of the clinical and economic evidence supporting VIASKIN Peanut.

Key Responsibilities

• Act as a subject matter expert on the health outcomes and economic impact of the VIASKIN Peanut Patch and the broader peanut allergy treatment landscape.
• Engage with national and regional payers, pharmacy benefit managers, integrated delivery networks, employers, and population health key opinion leaders to provide scientific, clinical, and economic information about VIASKIN Peanut.
• Communicate the value proposition of epicutaneous immunotherapy, including efficacy, safety, patch wear-time, and real-world relevance, to support informed coverage and formulary decisions.
• Conduct educational programs, scientific presentations, and value-evidence discussions to enhance understanding of product outcomes data among payer and population health audiences.
• Establish and maintain strong relationships with key external stakeholders, including medical and pharmacy directors, payer decision-makers, professional societies, and patient advocacy organizations in the food allergy community.
• Disseminate health outcomes data, real-world evidence, health economic models, and budget-impact analyses to support informed decision-making by payers and population health customers.
• Collaborate with internal cross-functional teams—including Market Access, Medical Affairs, Value & Access, Commercial, and Field Reimbursement—to align evidence strategies and ensure consistent, accurate messaging ahead of and through launch.
• Ensure that all communication and interactions comply with regulatory requirements, legal guidance, and company policies.

Qualifications

• PharmD, M.D., or Ph.D. in a health sciences–related field required; Master’s in pharmacoepidemiology, epidemiology, or health economics preferred.
• Minimum of eight (8) years working in the pharmaceutical, biotechnology, or healthcare industry, with a minimum of five (5) years in a HEOR or payer-facing scientific function supporting product launches with U.S. Market Access teams.
• Experience spanning medical and scientific affairs, outcomes research, clinical practice, academic, or U.S. managed-markets settings.
• Therapeutic experience in allergy/immunology, pediatrics, and/or rare disease preferred; familiarity with the food allergy treatment landscape is a strong advantage.
• Strong understanding of health outcomes research, epidemiology, and health economics. Demonstrated experience engaging national and regional payers, PBMs, IDNs, and other organized customers in a scientific or value-evidence capacity.
• Demonstrated expertise in economic modeling, budget-impact analysis, data analysis, and interpreting clinical and real-world data to generate meaningful insights.
• Stay updated on the latest industry trends, healthcare policies, and regulations impacting health economics and outcomes research, including those specific to pediatric and food allergy markets.
• Maintain a deep understanding of therapeutic areas of interest to the organization, including disease mechanisms, the treatment landscape, and relevant market dynamics.
• Excellent communication and presentation skills.
• Strong proficiency with relevant regulatory guidelines and requirements related to HEOR studies and payer scientific exchange.
• Understanding of compliance and ethical considerations in conducting research and engaging with payer decision-makers.
• Possess excellent written and verbal communication skills to effectively convey complex HEOR concepts to both technical and non-technical stakeholders.
• Ability to articulate clearly and conduct verbal presentations with large and small audiences.

About DBV Technologies

DBV Technologies is a global clinical stage biopharmaceutical company founded by pediatricians who believed that food allergies could one day be treated safely and effectively. We are on a mission to advance epicutaneous immunotherapy using our innovative technology platform, Viaskin™, to develop treatment options for immunologic diseases with significant unmet medical need. This mission drives our commitment to the advancement of treatments for patients and their families. That is why we are investigating a potential new class of immunotherapy, epicutaneous immunotherapy (EPIT), that aims to re-educate the immune system of patients through the skin. Today, we are focused on exploring the use of Viaskin to address food allergies, a devastating condition that afflicts millions of patients. As an important milestone in our journey, we hope to offer the first epicutaneous immunotherapy treatment for peanut allergy. Tomorrow, as pioneers, we will continue to explore the broad applications of this potential new class of immunotherapy, including treatments for patients suffering from inflammatory and autoimmune diseases.